AI's true potential lies in its ability to enhance human capabilities, not replace them. Photo via Getty Images

The rapid advancement of artificial intelligence is forcing businesses to evaluate how they will manage the inevitable changes this technology will bring. With its ability to automate tasks, analyze large amounts of data, and provide detailed insights, AI offers an enormous opportunity for businesses of all sizes. However, realizing this potential requires a strategic approach that positions AI as a powerful partner, rather than a replacement for human ingenuity.

The British Council reports that an estimated 65 percent of today's students will eventually work in professions that have yet to be conceived. With the emergence of new AI, this projection emphasizes the importance of cultivating a versatile skill set that allows us to adapt to the ever-changing landscape. It also underscores the importance of having a strategy that embraces the division of labor between humans and machines.

What this means is that an AI strategy shouldn't just be about automation – it should also incorporate an understanding of the human-AI partnership that will be necessary for future success. By using the concepts of automation, augmentation, and autonomy, businesses can unlock the full potential of AI to boost efficiency, enhance decision-making, and ultimately drive continued success.

Automation: Delegating to the AI

We know AI can automate many tasks in a business. However, we should also look at automation from a strategy standpoint by asking, "What tasks can be fully delegated to the AI?" Answering this question might include considering routine, repetitive, and time-consuming tasks that shouldn't require human intervention or those that would be more susceptible to human error. The goal here should be to identify tasks that don't benefit from human nuance, meaning asking questions about time, precision, and compliance could offer even more value.

  • Time. What tasks are time-consuming and could be completed quickly with well-written instructions?
  • Precision. What tasks require precision that is difficult for humans to achieve?
  • Compliance. What tasks involve critical safety procedures or adherence to strict compliance that humans might overlook?

Augmentation: Using AI to boost your potential

Beyond automation, AI's true power lies in its ability to boost human capabilities. In this lens, you should ask, "How can the AI boost my output potential?" Think of AI as a skilled assistant that can analyze vast datasets, identify complex patterns, and present insights that aren't readily apparent to humans alone. The focus here is on tasks that still require a human touch but can benefit from computers' speed and data processing power. When exploring this further, consider asking questions about skill boosts, assistance, and focus.

  • Skill boosts. What tasks am I doing that I understand but need to be an expert at?
  • Assistance. What tasks still require a human's touch but could use processing or speed boosts?
  • Focus. What tasks are causing employees to spend more time on tools and less on goals?

Autonomy: The importance of humans in the loop

One question that comes up frequently when discussing AI is whether it will replace a particular set of jobs. My thoughts, however, are that while AI is remarkably powerful, the key to making all this work is understanding that not every task requires automation. In fact, some tasks would suffer from automation. This step requires you to ask, "Where are human emotion, creativity, intuition, and oversight essential?" Autonomy, in this sense, means digging into creativity, intuition, and uniqueness.

  • Creativity. Does this task require a level of creativity that a machine can't replicate?
  • Intuition. Does this task require emotional awareness that a machine can't discern?
  • Brand Uniqueness. Does this task represent a part of my brand that shouldn't be automated or machine-driven?

AI brings a lot to look forward to. It’s fair to say it’s on its way to transforming the world, but it's important to remember that the businesses that strategically embrace a human-centered approach to integrating AI into everyday business activities are the ones that will thrive. The three A’s: automation, augmentation, and autonomy, provide an essential foundation to begin this journey. By understanding the best applications for each aspect of AI, businesses of all sizes can discover areas for increased efficiency, more thoughtful decision-making, and a competitive edge that drives long-term success. AI's true potential lies in its ability to enhance human capabilities, not replace them.

------

Kelsey Ruger is the chief technology and product officer for Hello Alice.

The concept is simple: Think before you act in marketing. Getty images

How to think before you act when it comes to marketing for your company

Strategizing for startups

If there were a joke about how entrepreneurs treat their marketing — and there totally isn't — it would go something like this.

An entrepreneur walks into a bar. Before the bartender can ask, the entrepreneur says, "I want a drink and I need it ASAP."

"What type of drink?", the bartender asks, motioning to the hundreds of bottles behind him.

"I need a drink that is refreshing, doesn't make me too drunk and makes me feel like I'm getting my money's worth."

The bartender begins listing drink after drink, and the entrepreneur, sometimes sampling the drink, turns each one down.

At long last, the entrepreneur climbs behind the bar, grabs a glass, pours in some ice and soda water, and takes a long sip.

"This is exactly what I wanted," the entrepreneur proclaims, "Why didn't you offer me this in the first place?"

The moral of the story? When it comes to marketing, entrepreneurs tend to know exactly what they want, yet they focus on quenching that immediate thirst, not knowing why they're in a bar in the first place.

The idea of your first step is nothing compared to the reality of your second. You can know something but applying those principles to starting and/or running your own business can be difficult.

When we (yes, I'm an entrepreneur too) look at marketing, we often confuse tactics with strategy. I see a problem and immediately need a tool to fix it. Hanging a picture? Where's the hammer?!

While it's tempting to lead with the tactics (i.e. website, brochure, display ad, video, etc.), they can be misguided. This can drain precious resources. Strategy can inject purpose into everyone's mindset.

Marketing efforts must be considered a sequence of events that, when lined up in the right order, produce results that are repeatable, more effective, and can lead to a predictable type of profitability.

Where careers rise and fall is the accuracy of any particular strategy. Since we're talking about accuracy, let's use an archery metaphor. Sure, you can consistently hit a target from five feet away. The farther away you get, though, the more you have to consider crosswind, the arrow's trajectory, and your own focus in order to hit that bullseye. And that's all part of a process of whittling down the variables you don't know or can't control.

It's the same with marketing. The more time you've spent preparing, studying, testing, and strategizing, the more often you will accurately target that bullseye.

Where a lot of entrepreneurs also miss the mark is not clearly understanding the core business issue. If you're lost in the forest (and it can totally feel like that sometimes), you're supposed to be quiet when hunting for food but you supposed to make a lot of noise when trying to get rescued. That's what mixing up a core business issue can do. As a process where you're whittling down the variables, marketing is a sequence, like this:

Graphic from Jarred King

Seems simple enough, right? But the process itself is dependent on the intangible pieces in between the steps. This is what happens between the "knowing" and the "doing." So, the above graph should really flow like this:

Graphic from Jarred King

Usually, the typical entrepreneur prefers to start with step four and just "get sh*t done." The problem with this approach is that it can either be the wrong solution (you're hunting with a rock instead of an arrow) or the wrong effort (you're staying quiet when you should be hollering).

The difficulty here is that the desired effect doesn't happen overnight. It rarely solves "today's problems" today. Even worse, it might require a larger investment. Without fundamentally understanding your business problem, any solution offered will be less effective, more expensive, and more wasteful of time and resources.

Instead, simply start with the business problem and then follow the above sequence to leverage "the doing" part in order to develop "the knowing" part. This doesn't have to be a drawn-out process, and there are a ton of free resources available online to help conduct your own research, analysis, and planning.

Ultimately, I'm saying "think before you act." It's not difficult to understand. The challenge for entrepreneurs is that they are faced with hundreds of important and, often, business-critical decisions each day. We can't help but to react, then decide, and move on. While our gut and grit got us to this point of success, it's strategy that will take us from surviving to thriving.

------

Jarred King is the founder and president of Swagger Agency, a full-service marketing firm as well as the current president of Entrepreneurs' Organization - Houston. King also serves on the board of InnovationMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.